Advanced Cell Technology Inc. range bound

Oct 29th, 2014 – 1 Comment

There are no signals at this time to suggest a move higher is in the cards.

About the Author

Lou Schizas is an equities analyst, investor, entrepreneur, professor and television and radio personality – and a true believer in the happiness-inspiring powers of capitalism.

Read the author's full profile.

Further Research

Read more about Stem Cell Therapy.

See also .



Dear Lou

I have been invested in ATCT since 2005. They had lots of problems which appear to have been cleaned up.
This company is changing their name to Ocata Therapeutics after the November 12, 2014 General Meeting.
I believe they will shortly list on the Nasdaq. I think this company sometime in the future will be like



Hey Ken,

Thanks for the assignment. is in clinical trials of its regenerative treatment for Stargardt’s macular degeneration, dry age related macular degeneration, and myoptic macular degeneration. Regenerative medicine involves replacing or regenerating human cells, tissues, and even organs. In the fact sheet posted on the company’s web site they refer to retinal pigment epithelium cells derived from embryonic stem cells.  The company is conducting preclinical research in the treatment of other ocular conditions as well as applications in autoimmune, and inflammatory therapies.

The best outcome for you as a longterm investor would be the listing of the shares on Nasdaq. The OTC Market is seen as a high risk market with limited reporting requirements that would keep many potential investors on the sidelines. I would also advise that if you have been long since 2005 that you should amend your expectations. ACTC traded at substantially higher levels nine years ago and a return to those levels would have, in my opinion, a low probability.

An examination of the charts will provide further research for you to add to the file for ACTC.








The three- year chart depicts a range bound pattern with support at $6.00 and resistance at $9.00. There was the September spike 2014 through $9.00 which wasn’t sustained as a breakout. The MACD and the RSI both signalled a buy in mid August and sell at the early September spike high near $13.00.








ACTC2The six-month chart provides a close up of the buy and sell signals generated by the momentum indicators. There are no patterns at this time to suggest a move higher is in the cards. As a long term investor trapped in stock that has given up a substantial amount of value you have to ask yourself when its time to tap out? Capital preservation is not an option its a requirement of effective asset management.

From the research conducted on your behalf ACTC is in the early stages of the clinical trials process. The conclusion of the trials is still further down the road suggesting that your nine year vigil has longer to go.

Make it a profitable day and happy capitalism!

Content © Relentless Economics - Charts courtesy - Employees Entrance - Optimization Media